ES2925215T3 - Sanfetrinem o una sal o éster del mismo para su uso en el tratamiento de una infección por micobacterias - Google Patents

Sanfetrinem o una sal o éster del mismo para su uso en el tratamiento de una infección por micobacterias Download PDF

Info

Publication number
ES2925215T3
ES2925215T3 ES18721053T ES18721053T ES2925215T3 ES 2925215 T3 ES2925215 T3 ES 2925215T3 ES 18721053 T ES18721053 T ES 18721053T ES 18721053 T ES18721053 T ES 18721053T ES 2925215 T3 ES2925215 T3 ES 2925215T3
Authority
ES
Spain
Prior art keywords
prodrug
mycobacterium
pharmaceutically acceptable
tuberculosis
mycobacterial infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18721053T
Other languages
English (en)
Spanish (es)
Inventor
Aguirre David Barros
Robert H Bates
Del Rio Ruben Gonzalez
Losana Alfonso Mendoza
Garcia Santiago Ramon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Application granted granted Critical
Publication of ES2925215T3 publication Critical patent/ES2925215T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D463/00—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D463/10—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D463/12—Heterocyclic compounds containing 1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals attached in position 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES18721053T 2017-05-08 2018-05-04 Sanfetrinem o una sal o éster del mismo para su uso en el tratamiento de una infección por micobacterias Active ES2925215T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382255 2017-05-08
PCT/EP2018/061615 WO2018206466A1 (en) 2017-05-08 2018-05-04 Sanfetrinem or a salt or ester thereof for use in treating mycobacterial infection

Publications (1)

Publication Number Publication Date
ES2925215T3 true ES2925215T3 (es) 2022-10-14

Family

ID=58709903

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18721053T Active ES2925215T3 (es) 2017-05-08 2018-05-04 Sanfetrinem o una sal o éster del mismo para su uso en el tratamiento de una infección por micobacterias

Country Status (22)

Country Link
US (1) US11253500B2 (enExample)
EP (1) EP3621609B1 (enExample)
JP (1) JP7123074B2 (enExample)
KR (1) KR102575872B1 (enExample)
CN (1) CN110869016B (enExample)
AU (1) AU2018265192B2 (enExample)
BR (1) BR112019023322B1 (enExample)
CA (1) CA3060396A1 (enExample)
CY (1) CY1125546T1 (enExample)
DK (1) DK3621609T3 (enExample)
ES (1) ES2925215T3 (enExample)
HR (1) HRP20221212T1 (enExample)
HU (1) HUE059818T2 (enExample)
LT (1) LT3621609T (enExample)
PL (1) PL3621609T3 (enExample)
PT (1) PT3621609T (enExample)
RS (1) RS63461B1 (enExample)
RU (1) RU2757272C2 (enExample)
SI (1) SI3621609T1 (enExample)
SM (1) SMT202200400T1 (enExample)
WO (1) WO2018206466A1 (enExample)
ZA (1) ZA201906810B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111184718A (zh) * 2018-11-15 2020-05-22 鲁南制药集团股份有限公司 法罗培南在制备治疗初治病原学阳性肺结核药物中的用途
CA3206024A1 (en) * 2021-02-01 2022-08-04 The Global Alliance For Tb Drug Development, Inc. Pretomanid amorphous form
CN117462551B (zh) * 2023-12-27 2024-05-17 深圳国家感染性疾病临床医学研究中心 茚地那韦和/或其衍生物在制备抗结核药物中的应用
CN122124048B (zh) * 2026-05-06 2026-07-24 深圳国家感染性疾病临床医学研究中心 埃替拉韦在制备结核分枝杆菌或非结核分枝杆菌的抑制剂中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ435990A3 (cs) 1989-09-08 1999-11-17 Glaxo S.P.A. Kyselina 10-(1-hydroxyethyl)-11-oxo-1-azatricyklo/7,2,0,03,8/-undec-2en-2-karboxylová a její deriváty, způsob jejich výroby, použití pro výrobu farmaceutických prostředků a farmaceutické prostředky s jejich obsahem
CA2067741C (en) 1990-08-21 2002-01-01 Alcide Perboni 10(1-hydroxyethly)-11-oxo-1-azatricyclo[7.2.0.0.3.8]undec-2-ene-2-carboxylic acid esters and a process for preparing thereof
GB9018330D0 (en) 1990-08-21 1990-10-03 Glaxo Spa Heterocyclic compounds
GB9104769D0 (en) 1991-03-07 1991-04-17 Glaxo Spa Heterocyclic compounds
GB9305813D0 (en) 1993-03-20 1993-05-05 Glaxo Spa Chemical process
EP2085084A1 (en) * 2008-01-29 2009-08-05 LEK Pharmaceuticals D.D. Use of inhibitor of beta-lactamases and its combination with beta-lactam antibiotics
EP2135871A1 (en) 2008-06-18 2009-12-23 LEK Pharmaceuticals D.D. New trinem antibiotics and inhibitors of beta-lactamases
WO2016046845A1 (en) 2014-09-25 2016-03-31 Manu Chaudhary Stealth, targeted nanoparticles (stn) for oral drug delivery
MA41495A (fr) 2015-02-12 2017-12-19 Anacor Pharmaceuticals Inc Composés benzoxaborole et leurs utilisations

Also Published As

Publication number Publication date
EP3621609B1 (en) 2022-07-27
KR20200003816A (ko) 2020-01-10
KR102575872B1 (ko) 2023-09-08
JP7123074B2 (ja) 2022-08-22
WO2018206466A1 (en) 2018-11-15
JP2020519592A (ja) 2020-07-02
BR112019023322B1 (pt) 2023-11-14
RS63461B1 (sr) 2022-08-31
HRP20221212T1 (hr) 2022-12-09
DK3621609T3 (da) 2022-08-29
EP3621609A1 (en) 2020-03-18
ZA201906810B (en) 2021-03-31
BR112019023322A2 (pt) 2020-06-16
SMT202200400T1 (it) 2022-11-18
LT3621609T (lt) 2022-10-10
RU2019139864A3 (enExample) 2021-06-28
SI3621609T1 (sl) 2022-10-28
CY1125546T1 (el) 2026-02-25
US11253500B2 (en) 2022-02-22
AU2018265192B2 (en) 2021-06-17
RU2757272C2 (ru) 2021-10-12
CN110869016B (zh) 2023-09-12
HUE059818T2 (hu) 2022-12-28
CN110869016A (zh) 2020-03-06
RU2019139864A (ru) 2021-06-09
PT3621609T (pt) 2022-08-24
AU2018265192A1 (en) 2019-11-07
PL3621609T3 (pl) 2022-11-14
CA3060396A1 (en) 2018-11-15
US20200289462A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
Veziris et al. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis
ES2905413T3 (es) Compuestos tricíclicos de benzoxaborol y usos de los mismos
EP3621609B1 (en) Sanfetrinem or a salt or ester thereof for use in treating mycobacterial infection
Lalloo et al. New antituberculous drugs in development
US20150031640A1 (en) Antibacterial agents: combination of a rifamycin and a switch region inhibitor
WO2014080378A1 (en) Phenothiazine derivatives and their use against tuberculosis
Diacon et al. From magic mountain to table mountain
CN113164456A (zh) 使用四环素化合物治疗分枝杆菌感染的方法
ES2833929T3 (es) Agente contra la tuberculosis
US20150209308A1 (en) Methods to inhibit intracellular growth of bacteria and to treat bacteria-mediated diseases
JP2020519592A5 (enExample)
Islam et al. In vitro activity of DNF-3 against drug-resistant Mycobacterium tuberculosis
TWI725948B (zh) 有效對抗包括抗藥性微生物類之微生物群的組合治療
BR112013030282B1 (pt) Composições compreendendo cefepima e tazobactama
JP2018526455A (ja) 抗生物質療法
Cheepsattayakorn et al. Novel compounds and drugs and recent patents in treating multidrug-resistant and extensively drug-resistant tuberculosis
Nikonenko et al. Preclinical study of new TB drugs and drug combinations in mouse models
WO2018019031A1 (en) A pharmaceutical composition comprising an ionophore and a beta-lactam antibiotic and use thereof
CN102138917A (zh) 二甲基黄青霉素在制备抗结核药物中的应用
WO2024175768A1 (en) Combination of fabi inhibitor and antibiotic agent
CN120379693A (zh) 一种药物组合及应用
Mashele Optimising the efficacy of clofazimine against biofilm-encased Mycobacterium tuberculosis
RU2595881C2 (ru) Применение нанофосфолипидной композиции рифампицина совместно с протионамидом или его нанофосфолипидной формой в лечении туберкулеза
WO2020119959A1 (en) Pharmaceutical composition for the treatment of cystic fibrosis
Phillips et al. Research Article Antimycobacterial Activities of Novel 5-(1H-1, 2, 3-Triazolyl) Methyl Oxazolidinones